Revenue from commercial sale of products relates to sale of SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. market, which is sold to specialty pharmacies and specialty distributors (“commercial customers”). Customer payment terms are typically 30 days from the transaction date. SKYTROFA was approved by the U.S. Food and Drug Administration in August 2021, and the Company began shipping products to commercial customers in the fourth quarter of 2021.

Other revenue is generated primarily from three license agreements, which were entered into in 2018. The licenses grant VISEN Pharmaceuticals (“VISEN”), exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China.

Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:


	2022		2021		2020
	(EUR’000)
Revenue
Commercial sale of products		35,659		943		—
Rendering of services		4,434		751		2,140
Sale of clinical supply		8,534		3,719		2,206
Licenses		2,547		2,365		2,607
Total revenue		51,174		7,778		6,953
Attributable to
Commercial customers		35,659		943		—
Collaboration partners and license agreements		15,515		6,835		6,953
Total revenue		51,174		7,778		6,953
Specified by timing of recognition
Recognized over time		4,434		751		2,140
Recognized at a point in time		46,740		7,027		4,813
Total revenue		51,174		7,778		6,953
Specified per geographical location
Europe		552		—		—
North America		44,156		6,856		2,679
China		6,466		922		4,274
Total revenue		51,174		7,778		6,953